European CHMP recommends intramuscular route of administration for peginterferon beta-1a (Plegridy)
The new intramuscular route of administration is intended for the existing formulation (125 micrograms in 0.5 ml) in the treatment of adult patients with relapsing remitting multiple sclerosis.
Source:
European Medicines Agency